Clinical Trials in Náchod, Czechia
12 recruiting
Showing 1–11 of 11 trials
Recruiting
Phase 3
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
Obesity and Overweight
Pfizer3,501 enrolled170 locationsNCT07311850
Recruiting
Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Graves Disease
Immunovant Sciences GmbH210 enrolled145 locationsNCT07018323
Recruiting
Phase 2
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
Atopic Dermatitis
UCB Biopharma SRL160 enrolled64 locationsNCT07277660
Recruiting
Phase 3
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
Urinary Incontinence, Stress
Eli Lilly and Company1,000 enrolled137 locationsNCT07202884
Recruiting
Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Hypertriglyceridemia
Arrowhead Pharmaceuticals869 enrolled275 locationsNCT06822790
Recruiting
Phase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Chronic Kidney Disease and Hypertension
AstraZeneca5,000 enrolled761 locationsNCT06742723
Recruiting
Phase 3
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
ObesityType 2 Diabetes
Novo Nordisk A/S2,500 enrolled303 locationsNCT07564414
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled772 locationsNCT07037433
Recruiting
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
ObesityHeart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection Fraction
Amgen5,056 enrolled605 locationsNCT07037459
Recruiting
Phase 3
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
ObesityOverweightType 2 Diabetes+2 more
Pfizer999 enrolled183 locationsNCT07400653
Recruiting
Early Detection of CTEPH in Patients After APE
Chronic Pulmonary Thromboembolism
Institute of Health Information and Statistics of the Czech Republic500 enrolled10 locationsNCT06865326